|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Tran L, Xiao JF, Agarwal N, Duex JE and
Theodorescu D: Advances in bladder cancer biology and therapy. Nat
Rev Cancer. 21:104–121. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Katims AB, Tallman J, Vertosick E, Porwal
S, Dalbagni G, Cha EK, Smith R, Benfante N and Herr HW: Response to
2 induction courses of bacillus Calmette-Guèrin therapy among
patients with high-risk non-muscle-invasive bladder cancer: 5-Year
follow-up of a phase 2 clinical trial. JAMA Oncol. 10:522–525.
2024.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Teoh JY, Kamat AM, Black PC, Grivas P,
Shariat SF and Babjuk M: Recurrence mechanisms of
non-muscle-invasive bladder cancer-a clinical perspective. Nat Rev
Urol. 19:280–294. 2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Knowles MA and Hurst CD: Molecular biology
of bladder cancer: New insights into pathogenesis and clinical
diversity. Nat Rev Cancer. 15:25–41. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Babjuk M, Böhle A, Burger M, Capoun O,
Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M,
et al: EAU guidelines on non-muscle-invasive urothelial carcinoma
of the bladder: Update 2016. Eur Urol. 71:447–461. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Berdik C: Unlocking bladder cancer.
Nature. 551:S34–S35. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
James AC and Gore JL: The costs of
non-muscle invasive bladder cancer. Urol Clin North Am. 40:261–269.
2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Abdollah F, Gandaglia G, Thuret R,
Schmitges J, Tian Z, Jeldres C, Passoni NM, Briganti A, Shariat SF,
Perrotte P, et al: Incidence, survival and mortality rates of
stage-specific bladder cancer in United States: A trend analysis.
Cancer Epidemiol. 37:219–225. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Witjes JA, Bruins HM, Cathomas R, Compérat
EM, Cowan NC, Gakis G, Hernández V, Linares Espinós E, Lorch A,
Neuzillet Y, et al: European association of urology guidelines on
muscle-invasive and metastatic bladder cancer: Summary of the 2020
guidelines. Eur Urol. 79:82–104. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Wang Y, Chang Q and Li Y: Racial
differences in urinary bladder cancer in the United States. Sci
Rep. 8(12521)2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Schinkel JK, Shao S, Zahm SH, McGlynn KA,
Shriver CD and Zhu K: Overall and recurrence-free survival among
black and white bladder cancer patients in an equal-access health
system. Cancer Epidemiol. 42:154–158. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kaye DR, Canner JK, Kates M, Schoenberg MP
and Bivalacqua TJ: Do African American patients treated with
radical cystectomy for bladder cancer have worse overall survival?
Accounting for pathologic staging and patient demographics beyond
race makes a difference. Bladder Cancer. 2:225–234. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Casey MF, Gross T, Wisnivesky J, Stensland
KD, Oh WK and Galsky MD: The impact of regionalization of
cystectomy on racial disparities in bladder cancer care. J Urol.
194:36–41. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Dobruch J, Daneshmand S, Fisch M, Lotan Y,
Noon AP, Resnick MJ, Shariat SF, Zlotta AR and Boorjian SA: Gender
and bladder cancer: A collaborative review of etiology, biology,
and outcomes. Eur Urol. 69:300–310. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Radkiewicz C, Edgren G, Johansson ALV,
Jahnson S, Häggström C, Akre O, Lambe M and Dickman PW: Sex
Differences in urothelial bladder cancer survival. Clin Genitourin
Cancer. 18:26–34.e6. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Babjuk M, Burger M, Compérat EM, Gontero
P, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF,
Sylvester R, et al: European association of urology guidelines on
non-muscle-invasive bladder cancer (TaT1 and carcinoma in
situ)-2019 update. Eur Urol. 76:639–657. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Messing EM, Tangen CM, Lerner SP,
Sahasrabudhe DM, Koppie TM, Wood DP Jr, Mack PC, Svatek RS, Evans
CP, Hafez KS, et al: Effect of intravesical instillation of
gemcitabine vs saline immediately following resection of suspected
low-grade non-muscle-invasive bladder cancer on tumor recurrence:
SWOG S0337 randomized clinical trial. JAMA. 319:1880–1888.
2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Monro S, Colón KL, Yin H, Roque J III,
Konda P, Gujar S, Thummel RP, Lilge L, Cameron CG and McFarland SA:
Transition metal complexes and photodynamic therapy from a
tumor-centered approach: Challenges, opportunities, and highlights
from the development of TLD1433. Chem Rev. 119:797–828.
2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sylvester RJ, van der Meijden APM and Lamm
DL: Intravesical bacillus Calmette-Guerin reduces the risk of
progression in patients with superficial bladder cancer: A
meta-analysis of the published results of randomized clinical
trials. J Urol. 168:1964–1970. 2002.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lamm DL, Blumenstein BA, Crissman JD,
Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB,
Beck TM, et al: Maintenance bacillus Calmette-Guerin immunotherapy
for recurrent TA, T1 and carcinoma in situ transitional cell
carcinoma of the bladder: A randomized southwest oncology group
study. J Urol. 163:1124–1129. 2000.PubMed/NCBI
|
|
22
|
Hermans TJN, Voskuilen CS, van der Heijden
MS, Schmitz-Dräger BJ, Kassouf W, Seiler R, Kamat AM, Grivas P,
Kiltie AE, Black PC and van Rhijn BWG: Neoadjuvant treatment for
muscle-invasive bladder cancer: The past, the present, and the
future. Urol Oncol. 36:413–422. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Shi W, Yuan R, Chen X, Xin Q, Wang Y,
Shang X, Cong W and Chen K: Puerarin reduces blood pressure
in spontaneously hypertensive rats by targeting eNOS. Am J Chin
Med. 47:19–38. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Shukla R, Pandey N, Banerjee S and
Tripathi Y: Effect of extract of Pueraria tuberosa on
expression of hypoxia inducible factor-1α and vascular endothelial
growth factor in kidney of diabetic rats. Biomed Pharmacother.
93:276–285. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Satpathy S, Patra A, Ahirwar B and Hussain
MD: Antioxidant and anticancer activities of green synthesized
silver nanoparticles using aqueous extract of tubers of
Pueraria tuberosa. Artif Cells Nanomed Biotechnol. 46 (Suppl
3):S71–S85. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Jearapong N, Chatuphonprasert W and
Jarukamjorn K: Miroestrol, a phytoestrogen from Pueraria
mirifica, improves the antioxidation state in the livers and uteri
of β-naphthoflavone-treated mice. J Nat Med. 68:173–180.
2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ahmad B, Khan S, Liu Y, Xue M, Nabi G,
Kumar S, Alshwmi M and Qarluq AW: Molecular mechanisms of
anticancer activities of Puerarin. Cancer Manag Res.
12:79–90. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Lin YJ, Hou YC, Lin CH, Hsu YA, Sheu JJ,
Lai CH, Chen BH, Lee Chao PD, Wan L and Tsai FJ: Puerariae
radix isoflavones and their metabolites inhibit growth and
induce apoptosis in breast cancer cells. Biochem Biophys Res
Commun. 378:683–688. 2009.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zhang XL, Wang BB and Mo JS:
Puerarin 6''-O-xyloside possesses significant antitumor
activities on colon cancer through inducing apoptosis. Oncol Lett.
16:5557–5564. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Bulugonda RK, Kumar KA, Gangappa D, Beeda
H, Philip GH, Muralidhara Rao D and Faisal SM: Mangiferin from
Pueraria tuberosa reduces inflammation via inactivation of
NLRP3 inflammasome. Sci Rep. 7(42683)2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Pandey N, Yadav D, Pandey V and Tripathi
VB: Anti-inflammatory effect of Pueraria tuberosa extracts
through improvement in activity of red blood cell anti-oxidant
enzymes. Ayu. 34:297–301. 2013.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Srivastava S, Pandey H, Singh SK and
Tripathi YB: Anti-oxidant, anti-apoptotic, anti-hypoxic and
anti-inflammatory conditions induced by PTY-2 against STZ-induced
stress in islets. Biosci Trends. 13:382–393. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Shukla R, Banerjee S and Tripathi YB:
Pueraria tuberosa extract inhibits iNOS and IL-6 through
suppression of PKC-α and NF-kB pathway in diabetes-induced
nephropathy. J Pharm Pharmacol. 70:1102–1112. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Jin SE, Son YK, Min BS, Jung HA and Choi
JS: Anti-inflammatory and antioxidant activities of constituents
isolated from Pueraria lobata roots. Arch Pharm Res.
35:823–837. 2012.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Kim JM, Lee YM, Lee GY, Jang DS, Bae KH
and Kim JS: Constituents of the roots of Pueraria lobata
inhibit formation of advanced glycation end products (AGEs). Arch
Pharm Res. 29:821–825. 2006.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Sun Y, Zhang H, Cheng M, Cao S, Qiao M,
Zhang B, Ding L and Qiu F: New hepatoprotective isoflavone
glucosides from Pueraria lobata (Willd.) Ohwi. Nat Prod Res.
33:3485–3492. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Sook Kim Y, Soo Lee I and Sook Kim J:
Protective effects of Puerariae radix extract and its single
compounds on methylglyoxal-induced apoptosis in human retinal
pigment epithelial cells. J Ethnopharmacol. 152:594–598.
2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Sucontphunt A, De-Eknamkul W, Nimmannit U,
Dan Dimitrijevich S and Gracy RW: Protection of HT22 neuronal cells
against glutamate toxicity mediated by the antioxidant activity of
Pueraria candollei var. mirifica extracts. J Nat Med.
65:1–8. 2011.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Koirala P, Seong SH, Jung HA and Choi JS:
Comparative evaluation of the antioxidant and anti-Alzheimer's
disease potential of coumestrol and puerarol isolated from
Pueraria lobata using molecular modeling studies. Molecules.
23(785)2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Anukulthanakorn K, Parhar IS, Jaroenporn
S, Kitahashi T, Watanbe G and Malaivijitnond S: Neurotherapeutic
effects of Pueraria mirifica extract in early- and
late-stage cognitive impaired rats. Phytother Res. 30:929–939.
2016.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Tiyasatkulkovit W, Malaivijitnond S,
Charoenphandhu N, Havill LM, Ford AL and VandeBerg JL:
Pueraria mirifica extract and Puerarin enhance
proliferation and expression of alkaline phosphatase and type I
collagen in primary baboon osteoblasts. Phytomedicine.
21:1498–1503. 2014.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Manonai J, Chittacharoen A, Udomsubpayakul
U, Theppisai H and Theppisai U: Effects and safety of
Pueraria mirifica on lipid profiles and biochemical markers
of bone turnover rates in healthy postmenopausal women. Menopause.
15:530–535. 2008.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Wang Y, Wang WL, Xie WL, Li LZ, Sun J, Sun
WJ and Gong HY: Puerarin stimulates proliferation and
differentiation and protects against cell death in human
osteoblastic MG-63 cells via ER-dependent MEK/ERK and PI3K/Akt
activation. Phytomedicine. 20:787–796. 2013.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Wang Y, Ma Y, Zheng Y, Song J, Yang X, Bi
C, Zhang D and Zhang Q: In vitro and in vivo anticancer activity of
a novel Puerarin nanosuspension against colon cancer, with
high efficacy and low toxicity. Int J Pharm. 441:728–735.
2013.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Jia L, Hu Y, Yang G and Li P:
Puerarin suppresses cell growth and migration in
HPV-positive cervical cancer cells by inhibiting the PI3K/mTOR
signaling pathway. Exp Ther Med. 18:543–549. 2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Zhang WG, Liu XF, Meng KW and Hu SY:
Puerarin inhibits growth and induces apoptosis in SMMC-7721
hepatocellular carcinoma cells. Mol Med Rep. 10:2752–2758.
2014.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Zhang WG, Yin XC, Liu XF, Meng KW, Tang K,
Huang FL, Xu G and Gao J: Puerarin induces hepatocellular
carcinoma cell apoptosis modulated by MAPK signaling pathways in a
dose-dependent manner. Anticancer Res. 37:4425–4431.
2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Hu Q, Xiang H, Shan J, Jiao Q, Lv S, Li L,
Li F, Ren D and Lou H: Two pairs of diastereoisomeric isoflavone
glucosides from the roots of Pueraria lobata. Fitoterapia.
144(104594)2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Shi ZD, Hao L, Han XX, Wu ZX, Pang K, Dong
Y, Qin JX, Wang GY, Zhang XM, Xia T, et al: Targeting HNRNPU to
overcome cisplatin resistance in bladder cancer. Mol Cancer.
21(37)2022.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Nandana PI, Rasyid H, Prihantono P,
Yustisia I, Hakim L, Bukhari A and Prasedya ES: Cytotoxicity and
apoptosis studies of brucein D against T24 bladder cancer cells.
Asian Pac J Cancer Prev. 25:921–930. 2024.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Sun Y, Liu X, Tong H, Yin H, Li T, Zhu J,
Chen J, Wu L, Zhang X, Gou X and He W: SIRT1 promotes cisplatin
resistance in bladder cancer via beclin1 deacetylation-mediated
autophagy. Cancers (Basel). 16(125)2023.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Mun JY, Baek SW, Jeong MS, Jang IH, Lee
SR, You JY, Kim JA, Yang GE, Choi YH, Kim TN, et al: Stepwise
molecular mechanisms responsible for chemoresistance in bladder
cancer cells. Cell Death Discov. 8(450)2022.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Dong J, Guo Y, Ji T, Gao Q, Guan H, Niu Y,
Ma Y and Rong S: Effect of Puerariae radix flavones on mRNA
expression of N-myc downstream regulatory gene 1 in bladder cancer
cell line T24. J Environ Health. 41:941–943. 2024.(In Chinese).
|
|
55
|
Vanden Berghe T, Linkermann A,
Jouan-Lanhouet S, Walczak H and Vandenabeele P: Regulated necrosis:
The expanding network of non-apoptotic cell death pathways. Nat Rev
Mol Cell Biol. 15:135–147. 2014.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Lavrik IN and Krammer PH: Regulation of
CD95/Fas signaling at the DISC. Cell Death Differ. 19:36–41.
2012.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Peter ME and Krammer PH: The
CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 10:26–35.
2003.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Rehm M, Huber HJ, Dussmann H and Prehn JH:
Systems analysis of effector caspase activation and its control by
X-linked inhibitor of apoptosis protein. EMBO J. 25:4338–4349.
2006.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Cheng J, Zhou T, Liu C, Shapiro JP, Brauer
MJ, Kiefer MC, Barr PJ and Mountz JD: Protection from Fas-mediated
apoptosis by a soluble form of the Fas molecule. Science.
263:1759–1762. 1994.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Kantari C and Walczak H: Caspase-8 and
bid: Caught in the act between death receptors and mitochondria.
Biochim Biophys Acta. 1813:558–563. 2011.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Sartorius U, Schmitz I and Krammer PH:
Molecular mechanisms of death-receptor-mediated apoptosis.
Chembiochem. 2:20–29. 2001.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Kaufmann T, Strasser A and Jost PJ: Fas
death receptor signalling: Roles of Bid and XIAP. Cell Death
Differ. 19:42–50. 2012.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Li H and Lin X: Positive and negative
signaling components involved in TNFalpha-induced NF-kappaB
activation. Cytokine. 41:1–8. 2008.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Wajant H and Scheurich P: TNFR1-induced
activation of the classical NF-κB pathway. FEBS J. 278:862–876.
2011.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Karin M: Nuclear factor-kappaB in cancer
development and progression. Nature. 441:431–436. 2006.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Luo JL, Tan W, Ricono JM, Korchynskyi O,
Zhang M, Gonias SL, Cheresh DA and Karin M: Nuclear
cytokine-activated IKKalpha controls prostate cancer metastasis by
repressing Maspin. Nature. 446:690–694. 2007.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Karin M and Lin A: NF-kappaB at the
crossroads of life and death. Nat Immunol. 3:221–227.
2002.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Ben-Neriah Y and Karin M: Inflammation
meets cancer, with NF-κB as the matchmaker. Nat Immunol.
12:715–723. 2011.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Baud V and Karin M: Is NF-kappaB a good
target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov.
8:33–40. 2009.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Vazquez-Santillan K, Melendez-Zajgla J,
Jimenez-Hernandez L, Martínez-Ruiz G and Maldonado V: NF-κB
signaling in cancer stem cells: A promising therapeutic target?
Cell Oncol (Dordr). 38:327–339. 2015.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Cao X and Jin HM: Effects of Fas, NF-κB
and caspases on microvascular endothelial cell apoptosis induced by
TNFα. Chin J Pathophysiol. 8:15–18. 2001.(In Chinese).
|
